Pr Alexander M. Eggermont of Institut Gustav Roussy in Paris and study coordinator of EORTC trial 18071, presented the initial efficacy and safety results from that phase III trial at ASCO 2014 in Chicago. This trial showed that adjuvant therapy with ipilimumab (Yervoy) for patients with high-risk stage III melanoma significantly improved recurrence-free survival. An overview of the trial results were reported 06 June 2014 in The ASCO Post.
Will adjuvant pembrolizumab improve recurrence-free survival for patients with high-risk Stage III melanoma?
Safeguarding the Future of Independent Academic Clinical Cancer Research – CAREFOR reaches out to the EU